Journal of microbiology, epidemiology and immunobiologyJournal of microbiology, epidemiology and immunobiologyЖурнал микробиологии, эпидемиологии и иммунобиологии0372-93112686-7613Central Research Institute for Epidemiology13882ArticlesСтатьиReview ArticleIMMUNOGENETIC FACTORS OF INTERACTION OF HEPATITIS C VIRUS AND HUMAN AND POSSIBILITIES OF DEVELOPMENT OF THERAPEUTIC TACTICИММУНОГЕНЕТИЧЕСКИЕ ФАКТОРЫ ВЗАИМОДЕЙСТВИЯ ВИРУСА ГЕПАТИТА С И ЧЕЛОВЕКА И ВОЗМОЖНОСТИ ВЫРАБОТКИ ТЕРАПЕВТИЧЕСКОЙ ТАКТИКИFedoseevaN. VФедосееваН. ВZnoikoO. OЗнойкоО. ОYuschukN. DЮщукН. ДMoscow State Medical-Stomatological University, RussiaМосковский государственный медико-стоматологический университет15062013903NO3 (2013)№3 (2013)9710309062023Copyright ©; 2013, Fedoseeva N.V., Znoiko O.O., Yuschuk N.D.Copyright ©; 2013, Федосеева Н.В., Знойко О.О., Ющук Н.Д.2013Fedoseeva N.V., Znoiko O.O., Yuschuk N.D.Федосеева Н.В., Знойко О.О., Ющук Н.Д.https://creativecommons.org/licenses/by/4.0https://microbiol.crie.ru/jour/article/view/13882

Various macroorganism factors influence spontaneous and therapy induced elimination of hepatitis C virus. Standard therapy is application of a combination of pegylated interfernos and ribavirin. However such tactics results in attainment of a resistant virological response in approximately half the cases during infection by genotype 1 virus. The future of viral hepatitis C therapy lies most probably in the sphere of application of specific antiviral preparations such as protease and/or polymerase inhibitors as an addition to standard therapy. The aim of this review was to describe mechanisms of resistance to therapy in light of reaction of innate and adaptive immune response as well as an attempt to determine factors capable of prognosing response to therapy.

На спонтанную и индуцированную лечением элиминацию вируса гепатита С влияют разнообразные факторы макроорганизма. Стандартная терапия представляет собой применение комбинации пегилированных интерферонов (PEG-IFN) и рибавирина. Однако такая тактика приводит к достижению устойчивого вирусологического ответа примерно в половине случаев при инфицировании 1 генотипом вируса. Будущее в лечении вирусного гепатита С, вероятнее всего, лежит в сфере применения в качестве дополнения к стандартной терапии специфических противовирусных препаратов, таких как протеазные и/или полимеразные ингибиторы. Цель настоящего обзора заключалась в описании механизмов устойчивости к терапии в свете реакций врожденного и адаптивного иммунного ответа, а также в попытке определения факторов, способных прогнозировать ответ на лечение.

hepatitis C virusIL-28Bimmunityinterferon stimulated genespegylated interferonboceprevirtelaprevirpolymerase inhibitorsprotease inhibitorsresistant virological responseвирус гепатита СИЛ-28Виммунитетинтерферон стимулированные геныпе-гилированный интерферонбоцепревиртелапревирполимеразные ингибиторыпротеазные ингибиторыустойчивый вирусологический ответBartosch B., Bukh J., Meunier G-C. et al. In vitro assay for neutralizing antibody to hepatitis C virus: Evidence for broadly conserved neutralization epitopes. Proceedings of the National Academy of Sciences of the United States ofAmerica. 2003, 100 (24): 14199-14204.Bartosch B., Verney G., Dreux. M et al. An interplay between hypervariable region 1 of the hepatitis C virus e2 glycoprotein, the scavenger receptor bi, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. Virology. 2005, 79: 8217-8229.Bing-Shui Xiu, Xiao-Yan Feng, Jing He et al. Evaluation of cross-reactive antibody response to HVR1 in chronic hepatitis C. World J. Gastroenterology. 2010, 16 (35): 4460-4466.Bode J.G., Brenndorfer E.D., Haussinger D. Hepatitis C virus (HCV) employs multiple strategies to subvert the host innate antiviral response. Biological Ohemistry. 2008, 389 (10): 1283-1298.Bolacchi F., Sinistro A., Ciaprini C. et al. Increased hepatitis C virus (HCV)-specific CD4+CD25+ regulatory T lymphocytes and reduced HCV-specific CD4+ T cell response in HCV-infected patients with normal versus abnormal alanine aminotransferase levels. Clin. Еxp. Immunol. 2006, 144 (2): 188196.Caterina Di Lorenzo, Allan G. N. et al. Hepatitis C virus evasion mechanisms from neutralizing antibodies. Viruses. 2011, 3: 2280-2300.Chang K.M., Thimme R., Melpolder J.J. et al. Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection. Hepatology. 2001, 33 (1): 267-276.Claassen M.A., de Knegt R.J., Tilanus H.W. et al. Abundant numbers of regulatory T cells localize to the liver of chronic hepatitis C infected patients and limit the extent of fibrosis. J. Hepatology. 2009, 52 (3): 315-321.Crotta S., Stilla A., Wack A. et al. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J. Exper. Med. 2002, 195: 35-42.Darling J.M. Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology. 2011, 53 (1): 14-22.Fukuda K., Umehara T, Sekiya S. et al. An RNA ligand inhibits hepatitis C virus NS3 protease and helicase activities. Biochem. Biophys. Res. Oom. 2004, 325 (3): 670-675.Ge D.L., Fellay J., Thompson A.J. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009, 461:399-401.Golden-Mason L., Bambha K. NK inhibitory receptor expression associated with treatment failure and IL-28B genotype in patients with chronic hepatitis C. Hepatology. 2011, 54 (5): 1559-1569.Guidotti L.G., Chisari F.V. Noncytolytic control of viral infections by the innate and adaptive immune response. Ann. Rev. Immunol. 2001, 19: 65-91.Isaguliants M.G., Widell A., Zhang S.M. et al. Antibody responses against B-cell epitopes of the hypervariable region 1 of hepatitis C virus in self-limiting and chronic human hepatitis C followed-up using consensus peptides. J. Med. Virol. 2002, 66 (20): 204-217.Kelly P. B., Andrea L. Hepatitis C virus evasion of adaptive immune responses - A model for viral persistence. Immunol Res. 2010, 47 (1-3): 216-227.Missale G., Cariani E., Ferrari C. Role of viral and host factors in HCV persistence: which lesson for therapeutic and preventive strategies? Digestive Liver Disease. 2004, 36 (11): 703-711.Miyaaki H., Zhou H., Ichikawa T. et al. Study of liver-targeted regulatory T cells in hepatitis B and C virus in chronically infected patients. Liver Inter. 2009, 29 (5): 702-707.Neumann-Haefelin C., Blum H.E., Chisari F.V. et al. T cell response in hepatitis C virus infection. Review. J. Clin. Virol. 2005, 32: 75-85.Penna A., Pilli M., Zerbini A. et al. Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection. Hepatology. 2007, 45 (3): 588-601.Rauch A., Kutalik Z., Descombes P. et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010, 138: 1338-1345.Ridruejo E., Solano A., Marciano S. et al. Genetic variation in interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin. Annals Hepatology. 2011, 10 (4): 452-457.Roederer M., Brenchley J.M., Betts M.R. et al. Flow cytometric analysis ofvaccine responses: how many colors are enough? Clin. Immunol. 2004, 110 (3): 199-205.Rutebemberwa A., Ray S.C., Astemborski J. et al. High programmed death-1 levels on hepatitis C vi-russpecific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection. J. Immunol. 2008, 181 (12): 8215-8225.Tanaka Y, Nishida N., Sugiyama M. et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009, 41: 1105-1109.Thimme R., Bukh J., Spangenberg H.C. et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proceedings of the National Academy of Sciences of the USA. 2002, 99: 15661-15668.Thomas D.L., Thio C.L., Martin M.P. et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009, 461: 798-801.Valli M.B., Crema A., Lanzilli G. et al. Molecular and cellular determinants of cell-to-cell transmission of hcv in vitro. J. Medical Virol. 2007, 79: 1491-1499.Zhang P., Zhong L., Struble E.B. et al. Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. Proceedings of the National Academy of Sciences of the USA. 2009, 106: 7537-7541.